Hyundai Bioscience to Conduct Global Clinical Trials for Dengue Antiviral Candidate

Hyundai Bioscience, a biotechnology company from South Korea, is focusing on global clinical development for a Dengue antiviral candidate to secure emergency use authorization. The CEO plans to conduct clinical tests targeting all Dengue virus serotypes, aiming for early administration of an effective antiviral drug. With a rise in Dengue cases globally, especially in the Americas, the need for a specific treatment is crucial. Hyundai Bioscience’s initiative in conducting extensive clinical trials signifies a significant step towards addressing the urgent need for a Dengue antiviral solution.